Chromium Picolinate Does Not Improve Key Features of Metabolic Syndrome in Obese Nondiabetic Adults
| Autor: | Richard A. Anderson, Serena Cardillo, Nayyar Iqbal, Philippe Szapary, Raymond C. Boston, LeAnne T. Bloedon, Sheri Volger |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Blood Glucose Male inorganic chemicals medicine.medical_specialty Time Factors Endocrinology Diabetes and Metabolism medicine.medical_treatment Type 2 diabetes Medication Adherence law.invention Double-Blind Method Randomized controlled trial law Internal medicine Diabetes mellitus otorhinolaryngologic diseases Internal Medicine medicine Humans Insulin Obesity Picolinic Acids Aged Metabolic Syndrome Philadelphia Academic Medical Centers Glucose tolerance test biology medicine.diagnostic_test business.industry C-reactive protein technology industry and agriculture Original Articles Glucose Tolerance Test Middle Aged medicine.disease Lipids Oxidative Stress C-Reactive Protein Treatment Outcome Endocrinology biology.protein Female Inflammation Mediators Metabolic syndrome business |
| Zdroj: | Metabolic Syndrome and Related Disorders. 7:143-150 |
| ISSN: | 1557-8518 1540-4196 |
| DOI: | 10.1089/met.2008.0048 |
| Popis: | The use of chromium-containing dietary supplements is widespread among patients with type 2 diabetes. Chromium's effects in patients at high risk for developing diabetes, especially those with metabolic syndrome, is unknown. The objective of this study was to determine the effects of chromium picolinate (CrPic) on glucose metabolism in patients with metabolic syndrome.A double-blind, placebo-controlled, randomized trial was conducted at a U.S. academic medical center. Sixty three patients with National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III)-defined metabolic syndrome were included. The primary end point was a change in the insulin sensitivity index derived from a frequently sampled intravenous glucose tolerance test. Prespecified secondary end points included changes in other measurements of glucose metabolism, oxidative stress, fasting serum lipids, and high sensitivity C-reactive protein.After 16 weeks of CrPic treatment, there was no significant change in insulin sensitivity index between groups (P = 0.14). However, CrPic increased acute insulin response to glucose (P 0.02). CrPic had no significant effect on other measures of glucose metabolism, body weight, serum lipids, or measures of inflammation and oxidative stress.CrPic at 1000 microg/day does not improve key features of the metabolic syndrome in obese nondiabetic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|